Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant
- Mlcochova P.
- Collier D.
- Ritchie A.
- Assennato S. M.
- Hosmillo M.
- Goel N.
- Meng B.
- Chatterjee K.
- Mendoza V.
- Temperton N.
- Kiss L.
- James L. C.
- Ciazynska K. A.
- Xiong X.
- Briggs J. A. G.
- Nathan J. A.
- Mescia F.
- Bergamaschi L.
- Zhang H.
- Barmpounakis P.
- Demeris N.
- Skells R.
- Lyons P. A.
- Bradley J.
- Baker S.
- Allain J. P.
- Smith K. G. C.
- Bousfield R.
- Wilson M.
- Sparkes D.
- Amoroso G.
- Gkrania-Klotsas E.
- Hardwick S.
- Boyle A.
- Goodfellow I.
- Gupta R. K.
- Baker S.
- Dougan G.
- Gupta R.
- Lehner P. J.
- Lyons P.
- Matheson N. J.
- Toshner M.
- Weekes M. P.
- Brown N.
- Curran M.
- Palmar S.
- Enoch D.
- Chapman D.
- Shaw A.
- Jose S.
- Bermperi A.
- Zerrudo J. A.
- Kourampa E.
- Watson L.
- Worsley J.
- Saunders C.
- de Jesus R.
- Domingo J.
- Pasquale C.
- Vergese B.
- Vargas P.
- Fabiculana M.
- Perales M.
- Mynott L.
- Blake E.
- Bates A.
- Vallier A. -L.
- Williams A.
- Phillips D.
- Chiu E.
- Overhill A.
- Ramenatte N.
- Sipple J.
- Frost S.
- Knock H.
- Hardy R.
- Foster E.
- Davidson F.
- Rundell V.
- Bundi P.
- Abeseabe R.
- Clark S.
- Vicente I.
- Elmer A.
- Ribeiro C.
- Kourampa J.
- Kennet J.
- Rowlands J.
- Meadows A.
- O'Brien C.
- Rastall R.
- Crucusio C.
- Hewitt S.
- Price J.
- Calder J.
- Canna L.
- Bucke A.
- Tordesillas H.
- Harris J.
- Ruffolo V.
- Graves B.
- Butcher H.
- Caputo D.
- Le Gresley E.
- Dunmore B. J.
- Martin J.
- Legchenko E.
- Treacy C.
- Huang C.
- Wood J.
- Sutcliffe R.
- Hodgson J.
- Shih J.
- Graf S.
- Tong Z.
- Tilly T.
- O'Donnell C.
- Hunter K.
- Pointon L.
- Pond N.
- Wylot M.
- Jones E.
- Fawke S.
- Bullman B.
- Turner L.
- Jarvis I.
- Omarjee O.
- De Sa A.
- Marsden J.
- Betancourt A.
- Perera M.
- Epping M.
- Richoz N.
- Bower G.
- Sharma R.
- Nice F.
- Huhn O.
- Savoinykh Yarkoni N.
- Romashova N.
- Lewis D.
- Hinch A.
- Cossetti C.
- Strezlecki M.
- Grenfell R.
- Stark H.
- Walker N.
- Stirrups K.
- Ovington N.
- Dewhust E.
- Li E.
- Papadia S.
- Kingston N.
- Lever A.
- Torok E.
- Hamilton W.
- Hall G.
- Jahun A.
- Chaudhry Y.
- Pinckert M.
- Georgana I.
- Yakovleva A.
- Caller L.
- Caddy S.
- Feltwell T.
- Khokhar F.
- Meredith L.
- Holdcroft C.
- Parmar S.
DOIAbstract
Rapid COVID-19 diagnosis in the hospital is essential, although this is complicated by 30%–50% of nose/throat swabs being negative by SARS-CoV-2 nucleic acid amplification testing (NAAT). Furthermore, the D614G spike mutant dominates the pandemic and it is unclear how serological tests designed to detect anti-spike antibodies perform against this variant. We assess the diagnostic accuracy of combined rapid antibody point of care (POC) and nucleic acid assays for suspected COVID-19 disease due to either wild-type or the D614G spike mutant SARS-CoV-2. The overall detection rate for COVID-19 is 79.2% (95% CI 57.8–92.9) by rapid NAAT alone. The combined point of care antibody test and rapid NAAT is not affected by D614G and results in very high...
Add to ORKG